Adherence to current guidelines for Chronic Obstructive Pulmonary Disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids

International Journal of COPD

Volumn 7, Issue , 2012, Pages 201-209

  Asche, Carl Victor ^a,b   Leader, Shelah ^c   Plauschinat, Craig ^c   Raparla, Swetha ^a   Yan, Ming ^a   Ye, Xiangyang ^a   Young, Dave ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adherence; Copd; Cost; Gold guidelines

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; CHI-SQUARE DISTRIBUTION; COST SAVINGS; DATABASES, FACTUAL; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MALE; MODELS, ECONOMIC; MUSCARINIC ANTAGONISTS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84860304497     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S25805     Document Type: Article

References (25)

1. The National Heart, Lung, and Blood Institute Health Information Center. Lung information. http://www.nhlbi.nih.gov/health/public/lung/ index.htm. Accessed March 25, 2010.
2. Center for Disease Control and Prevention. Facts about chronic obstructive pulmonary disease (COPD). http://www.cdc.gov/copd/copdfaq. htm. Accessed March 23, 2010.
3. Skrepnek GH, Skrepnek SV. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care. Jul 2004;10(Suppl 5):S129-S138.
4. Tovar JM, Gums JG. Monitoring pulmonary function in asthma and COPD: point-of-care testing. Ann Pharmacother. 2004;38(1):126-133.
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2008 update. http://www.goldcopd. com. Accessed March 22, 2010.
6. Daimon T, Fujimoto K, Tanaka K, et al. Volume of pulmonary lobes and segments in chronic obstructive pulmonary diseases calculated using newly developed three-dimensional software. Jpn J Radiol. Apr 2009;27(3):115-122.
7. Bresnitz EA. Epidemiology of advanced lung disease in the United States. Clin Chest Med. 1997;18(3):421-433.
8. Kabir Z, Connolly GN, Koh HK, Clancy L. Chronic Obstructive Pulmonary Disease hospitalization rates in Massachusetts: a trend analysis. QJM. 2010;103(3):163-168.
9. Edelman NH, Kaplan RM, Buist AS, et al. Chronic obstructive pulmonary disease. Task Force on Research and Education for the Prevention and Control of Respiratory Diseases. Chest. 1992;102(3 Suppl):243S-256S.
10. Buist AS. Guidelines for the management of chronic obstructive pulmonary disease. Respir Med. 2002;96 Suppl C:S11-S16.
11. Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest. 2000;117(2 Suppl):33S-37S.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
13. United States Department of Labor. Consumer Price Index for Medical Care. http://www.bls.gov/CPI/. Accessed October 15, 2009.
14. Lusuardi M, Lucioni C, De Benedetto F, Mazzi S, Sanguinetti CM, Donner CF. GOLD severity stratification and risk of hospitalisation for COPD exacerbations. Monaldi Arch Chest Dis. 2008;69(4):164-169.
15. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med. 1999;93(3):173-179.
16. Esteban C, Moraza J, Quintana JM, Aburto M, Capelastegui A. Use of medication and quality of life among patients with COPD. Respir Med. 2006;100(3):487-495.
17. López Varela MV, Muino A, Pérez Padilla R, et al. Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study. Arch Bronconeumol. 2008;44(2):58-64.
18. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002;20(4): 799-805.
19. Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2001;18(6):903-908.
20. Glaab T, Banik N, Rutschmann OT, Wencker M. National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD. 2006;3(3):141-148.
21. Decramer M, Bartsch P, Pauwels R, Yernault JC. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis. 2003;59(1):62-80.
22. Izquierdo-Alonso JL, de Miguel-Díez J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD. 2004;1(2):215-223.
23. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20(4):819-825.
24. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
25. Incalzi RA, Corsonello A, Pedone C, et al. From Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines to current clinical practice: an overview of the pharmacological therapy of stable chronic obstructive pulmonary disorder. Drugs Aging. 2006;23(5): 411-420.